Specifically, a study in stage III/IV NSCLC patients (n = 103) found that high baseline serum IL-6 (> 13.8 pg/ml) associated with worse PFS (p = 0.007) and OS (p = 0.003) following anti-PD-L1 as monotherapy or in combination with chemotherapy [25]. The gene discussed is IL6; the disease is non-small cell lung carcinoma.